pinex 500 mg suppositorier
teva b.v. - paracetamol - suppositorier - 500 mg
pinex junior 24 mg/ml oral opløsning
teva b.v. - paracetamol - oral opløsning - 24 mg/ml
pinex junior 125 mg suppositorier
teva b.v. - paracetamol - suppositorier - 125 mg
pinex retard 500 mg depottabletter
teva b.v. - paracetamol - depottabletter - 500 mg
pinex smelt 250 mg smeltetabletter
actavis group ptc ehf. - paracetamol - smeltetabletter - 250 mg
pinex smelt 500 mg smeltetabletter
actavis group ptc ehf. - paracetamol - smeltetabletter - 500 mg
arax hot 500 mg pulver til oral opløsning, breve
vitabalans oy - paracetamol - pulver til oral opløsning, breve - 500 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
apotel 10 mg/ml infusionsvæske, opløsning
uni-pharma kleon - paracetamol - infusionsvæske, opløsning - 10 mg/ml
arax extra 500 mg+65 mg tabletter
vitabalans oy - caffein, paracetamol - tabletter - 500 mg+65 mg